The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: Insights from the Leukemia and Lymphoma Society Registry Research Letter

  

Authors:	Luttwak, E.; Noy, A.; Seshan, V.; Saltzman, L. A.; Greenberger, L. M.
Title:	The efficacy of tixagevimab–cilgavimab prophylaxis against Omicron BA.5 variants in patients with hematological malignancies: Insights from the Leukemia and Lymphoma Society Registry
Keywords:	adult; clinical article; leukemia; mortality; letter; multiple myeloma; food and drug administration; t cell lymphoma; disease severity; hematologic malignancy; hematologic neoplasms; lymphoma; health care personnel; cancer registry; immune deficiency; immunosuppressive treatment; chronic lymphatic leukemia; hematologic disease; mortality rate; pre-exposure prophylaxis; humans; human; male; female; coronavirus disease 2019; cilgavimab plus tixagevimab; cilgavimab; tixagevimab; breakthrough infection; antigenic escape; emergency use authorization; sars-cov-2 (lineage ba.2); sars-cov-2 (lineage ba.4); sars-cov-2 (lineage ba.5); variant of concern
Journal Title:	Leukemia and Lymphoma
Volume:	64
Issue:	10
ISSN:	1042-8194
Publisher:	Taylor & Francis Group
Date Published:	2023-01-01
Start Page:	1727
End Page:	1729
Language:	English
DOI:	10.1080/10428194.2023.2227749
PUBMED:	37384591
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85163783174&doi=10.1080%2f10428194.2023.2227749&partnerID=40&md5=cd2a0071a2c4be698be28e199381c0c3
Notes:	Letter -- MSK corresponding author is Efrat Luttwak -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/210681